Butyrate Histone Deacetylase Inhibitors
暂无分享,去创建一个
[1] C. Pinkert,et al. Protection by an antioxidant of rotenone-induced neuromotor decline, reactive oxygen species generation and cellular stress in mouse brain , 2012, Pharmacology Biochemistry and Behavior.
[2] A. Nudelman,et al. A histone deacetylase inhibitory prodrug - butyroyloxymethyl diethyl phosphate - protects the heart and cardiomyocytes against ischemia injury. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[3] I. Goethals,et al. In vitro 2-deoxy-2-[18F]fluoro-D-glucose uptake: practical considerations. , 2012, Cancer biotherapy & radiopharmaceuticals.
[4] Udayanath Aich,et al. Metabolic oligosaccharide engineering with N‐Acyl functionalized ManNAc analogs: Cytotoxicity, metabolic flux, and glycan‐display considerations , 2012, Biotechnology and bioengineering.
[5] P. Jagodziński,et al. Effect of butyrate on aromatase cytochrome P450 levels in HT29, DLD-1 and LoVo colon cancer cells. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[6] A. Basu,et al. Epigenetic regulation of self‐renewal and fate determination in neural stem cells , 2012, Journal of neuroscience research.
[7] R. Berni Canani,et al. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice , 2012, Clinical Epigenetics.
[8] Robert M. Williams,et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. , 2012, Blood.
[9] M. Sun,et al. Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. , 2012, Genetics and molecular research : GMR.
[10] P. Mali,et al. Concise Review: Human Cell Engineering: Cellular Reprogramming and Genome Editing , 2012, Stem cells.
[11] D. Hadjipavlou-Litina,et al. Histone deacetylase inhibitors (HDACIs). Structure—activity relationships: history and new QSAR perspectives , 2012, Medicinal research reviews.
[12] R. Grundy,et al. Histone deacetylase inhibition as an anticancer telomerase‐targeting strategy , 2011, International journal of cancer.
[13] R. Machado-Vieira,et al. Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene‐Environment Interactions , 2011, CNS neuroscience & therapeutics.
[14] F. Crea,et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[15] S. Bates,et al. Histone deacetylase inhibitors: emerging mechanisms of resistance. , 2011, Molecular pharmaceutics.
[16] X. Coumoul,et al. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex , 2011, International journal of cancer.
[17] David E. Williams,et al. Metabolism as a key to histone deacetylase inhibition , 2011, Critical reviews in biochemistry and molecular biology.
[18] P. Bertrand,et al. Interpreting clinical assays for histone deacetylase inhibitors. , 2011, Cancer management and research.
[19] Jennifer J Westendorf,et al. Histone deacetylases in skeletal development and bone mass maintenance. , 2011, Gene.
[20] M. Esteller,et al. Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.
[21] Anthony E. Boitano,et al. Chemical control of stem cell fate and developmental potential. , 2011, Angewandte Chemie.
[22] C. Pinkert,et al. D-galactose effectiveness in modeling aging and therapeutic antioxidant treatment in mice. , 2010, Rejuvenation research.
[23] Nessa Carey,et al. Epigenetic therapies for non-oncology indications. , 2010, Drug discovery today.
[24] D. Faller,et al. A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers , 2010, British journal of haematology.
[25] E. Lam,et al. Butyrate-rich Colonic Microenvironment Is a Relevant Selection Factor for Metabolically Adapted Tumor Cells* , 2010, The Journal of Biological Chemistry.
[26] D. Faller,et al. Fetal globin gene inducers: novel agents and new potential , 2010, Annals of the New York Academy of Sciences.
[27] H. Fang,et al. Strategies in developing promising histone deacetylase inhibitors , 2010, Medicinal research reviews.
[28] Yi Zhang,et al. Butyrate Promotes Induced Pluripotent Stem Cell Generation* , 2010, The Journal of Biological Chemistry.
[29] Ying Sun,et al. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. , 2010, Chemico-biological interactions.
[30] E. Ho,et al. Dietary Manipulation of Histone Structure and Function , 2010, Lifestyle Genomics.
[31] S. Baylin,et al. Butyrate Greatly Enhances Derivation of Human Induced Pluripotent Stem Cells by Promoting Epigenetic Remodeling and the Expression of Pluripotency‐Associated Genes , 2010, Stem cells.
[32] R. Wanders,et al. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation , 2010, Journal of Inherited Metabolic Disease.
[33] Jeffrey Perkel. Histone code-breakers: the technologies of an epigenetic enigma. , 2010, BioTechniques.
[34] Yixue Li,et al. Regulation of Cellular Metabolism by Protein Lysine Acetylation , 2010, Science.
[35] S. McMahon,et al. Rise of the Rival , 2010, Science.
[36] Delong Liu,et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.
[37] J. Cueva,et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. , 2010, Cancer treatment reviews.
[38] Robert M. Williams,et al. Discovery, Biological Activity, Synthesis and Potential Therapeutic Utility of Naturally Occurring Histone Deacetylase Inhibitors , 2010 .
[39] P. Seeberger,et al. Carbohydrates: A Frontier in Medicinal Chemistry , 2009 .
[40] Qi-Long Ying,et al. Differentiation of mouse embryonic stem cells into hepatocytes induced by a combination of cytokines and sodium butyrate , 2009, Journal of cellular biochemistry.
[41] T. Enver,et al. Forcing cells to change lineages , 2009, Nature.
[42] M. A. Meledeo,et al. Hexosamine analogs: from metabolic glycoengineering to drug discovery. , 2009, Current opinion in chemical biology.
[43] D. Wagner,et al. The stem cell--chromatin connection. , 2009, Seminars in cell & developmental biology.
[44] K. Kang,et al. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells , 2009, Cell proliferation.
[45] Shu-Chen Lu,et al. Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity , 2009, Chemical biology & drug design.
[46] C. Hoppel,et al. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? , 2009, Advanced drug delivery reviews.
[47] Haishan Wang,et al. New patented histone deacetylase inhibitors , 2009, Expert opinion on therapeutic patents.
[48] Danny Reinberg,et al. Histones: annotating chromatin. , 2009, Annual review of genetics.
[49] M. Morgan,et al. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. , 2009, Chemical communications.
[50] S. McMahon,et al. Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells. , 2009, Trends in biochemical sciences.
[51] E. Levy,et al. In vitro studies on the inhibition of colon cancer by butyrate and carnitine. , 2009, Nutrition.
[52] D. Faller,et al. Lactic acid in cancer and mitochondrial disease , 2009 .
[53] J. Workman,et al. Introducing the acetylome , 2009, Nature Biotechnology.
[54] L. Monteggia,et al. Synergistic Interactions between Histone Deacetylase Inhibitors and Drugs of Abuse , 2009, Neuropsychopharmacology.
[55] M. Mann,et al. Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.
[56] J. Buggy,et al. Isoform-specific histone deacetylase inhibitors: the next step? , 2009, Cancer letters.
[57] D. Chuang,et al. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain , 2009, Journal of neurochemistry.
[58] Xue-Long Sun,et al. Recent developments in carbohydrate‐decorated targeted drug/gene delivery , 2009, Medicinal research reviews.
[59] K. Yelekçi,et al. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. , 2009, Bioorganic & medicinal chemistry.
[60] N. Habermann,et al. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. , 2009, Mutation research.
[61] Michael Bots,et al. Rational Combinations Using HDAC Inhibitors , 2009, Clinical Cancer Research.
[62] E. Purgatto,et al. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug , 2009, International journal of cancer.
[63] D. Faller,et al. Erythroid Kruppel‐like factor (EKLF) is recruited to the γ‐globin gene promoter as a co‐activator and is required for γ‐globin gene induction by short‐chain fatty acid derivatives , 2009, European journal of haematology.
[64] L. Altucci,et al. Histone acetyltransferase inhibitors and preclinical studies , 2009, Expert opinion on therapeutic patents.
[65] M. Rowley,et al. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. , 2009, Journal of medicinal chemistry.
[66] S. Haggarty,et al. HDAC2 negatively regulates memory formation and synaptic plasticity , 2009, Nature.
[67] Robert Brown,et al. The promises and pitfalls of epigenetic therapies in solid tumours. , 2009, European journal of cancer.
[68] Raja R Srinivas,et al. Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. , 2009, Journal of medicinal chemistry.
[69] W. Cefalu,et al. Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice , 2009, Diabetes.
[70] R. Marino,et al. Probiotic in lamb rennet paste enhances rennet lipolytic activity, and conjugated linoleic acid and linoleic acid content in Pecorino cheese. , 2009, Journal of dairy science.
[71] W. Ma,et al. Novel Agents on the Horizon for Cancer Therapy , 2009, CA: a cancer journal for clinicians.
[72] Ivars Kalvinsh,et al. Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR. , 2009, European journal of medicinal chemistry.
[73] Zhihong Zhang,et al. Identification and verification of lysine propionylation and butyrylation in yeast core histones using PTMap software. , 2009, Journal of proteome research.
[74] A. Munshi,et al. Histone modifications dictate specific biological readouts. , 2009, Journal of genetics and genomics = Yi chuan xue bao.
[75] C. Chaumontet,et al. Butyrate metabolism in human colon carcinoma cells: Implications concerning its growth‐inhibitory effect , 2009, Journal of cellular physiology.
[76] Udayanath Aich,et al. Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. , 2008, Journal of medicinal chemistry.
[77] Christopher E. Berndsen,et al. Catalysis and substrate selection by histone/protein lysine acetyltransferases. , 2008, Current opinion in structural biology.
[78] Michael J. Meaney,et al. Diet and the epigenetic (re)programming of phenotypic differences in behavior , 2008, Brain Research.
[79] Brian C. Smith,et al. Mechanisms and molecular probes of sirtuins. , 2008, Chemistry & biology.
[80] D. Schrenk,et al. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. , 2008, The Journal of nutritional biochemistry.
[81] M. Addis,et al. The use of lamb rennet paste in traditional sheep milk cheese production , 2008 .
[82] Wenfang Xu,et al. Synthesis of Carnitine Benzyl Esters as Prodrugs , 2008 .
[83] A. Nudelman,et al. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex) , 2008, Clinical & Experimental Metastasis.
[84] E. Ferreira,et al. Prodrugs for the Treatment of Neglected Diseases , 2008, Molecules.
[85] O. Piermatti,et al. Synthesis and characterization of carnitine nitro-derivatives. , 2008, Bioorganic & medicinal chemistry.
[86] Joshua Close,et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). , 2008, Bioorganic & medicinal chemistry letters.
[87] M. Egorin,et al. Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[88] Melissa Chenard,et al. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). , 2008, Bioorganic & medicinal chemistry letters.
[89] V. Ganapathy,et al. Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[90] Yukihiro Itoh,et al. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. , 2007, Journal of medicinal chemistry.
[91] E. Ho,et al. Dietary histone deacetylase inhibitors: from cells to mice to man. , 2007, Seminars in cancer biology.
[92] T. Beckers,et al. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors. , 2007, Journal of medicinal chemistry.
[93] Yi Tang,et al. Lysine Propionylation and Butyrylation Are Novel Post-translational Modifications in Histones*S , 2007, Molecular & Cellular Proteomics.
[94] M. K. Pflum,et al. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. , 2007, Bioorganic & medicinal chemistry letters.
[95] D. Riester,et al. Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases , 2007, Applied Microbiology and Biotechnology.
[96] C. Klein,et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. , 2007, Blood.
[97] K. Yarema,et al. Metabolic oligosaccharide engineering: perspectives, applications, and future directions. , 2007, Molecular bioSystems.
[98] M. A. Meledeo,et al. Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. , 2006, Chemistry & biology.
[99] D. Faller,et al. Identification of Novel Small‐molecule Inducers of Fetal Hemoglobin Using Pharmacophore and ‘PSEUDO’ Receptor Models , 2006, Chemical biology & drug design.
[100] V. Ganapathy,et al. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. , 2006, Life sciences.
[101] K. Gilbert,et al. Structure-activity relationship between carboxylic acids and T cell cycle blockade. , 2006, Life sciences.
[102] A. Nudelman,et al. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs , 2006, Investigational New Drugs.
[103] S. Vandenberg,et al. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas , 2005, Molecular Cancer Therapeutics.
[104] D. Faller,et al. Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. , 2005, Blood cells, molecules & diseases.
[105] C. Chen,et al. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. , 2005, Journal of medicinal chemistry.
[106] C. Monneret. Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.
[107] Steven Jupe,et al. A family of fatty acid binding receptors. , 2005, DNA and cell biology.
[108] R. Cecchelli,et al. Carnitine: transport and physiological functions in the brain. , 2004, Molecular aspects of medicine.
[109] Steven J. Miller. Cellular and physiological effects of short-chain fatty acids. , 2004, Mini reviews in medicinal chemistry.
[110] O. Witt,et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. , 2003, Blood.
[111] B. Pace,et al. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. , 2002, Blood.
[112] S. Horiuchi,et al. Sodium butyrate induces growth arrest and senescence‐like phenotypes in gynecologic cancer cells , 2001, International journal of cancer.
[113] S. Sampson,et al. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. , 2001, European journal of medicinal chemistry.
[114] B. Pace,et al. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. , 2001, Blood.
[115] Tony Kouzarides,et al. Acetylation: a regulatory modification to rival phosphorylation? , 2000, The EMBO journal.
[116] C. Allis,et al. The language of covalent histone modifications , 2000, Nature.
[117] G. Stamatoyannopoulos,et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. , 1999, Blood.
[118] D. Faller,et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.
[119] Minoru Yoshida,et al. [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[120] L. Bieber,et al. Possible functions of short-chain and medium-chain carnitine acyltransferases. , 1982, Federation proceedings.
[121] F. Knoop. The Degradation of Aromatic Fatty Acids in the Animal Body , 1968 .
[122] Honglin Jiang,et al. Butyrate activates the cAMP-protein kinase A-cAMP response element-binding protein signaling pathway in Caco-2 cells. , 2012, The Journal of nutrition.
[123] Antonio Calignano,et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. , 2011, World journal of gastroenterology.
[124] M. Eisenstein. IPSCs: One cell to rule them all? , 2010, Nature Methods.
[125] D. Wallace,et al. Energetics, epigenetics, mitochondrial genetics. , 2010, Mitochondrion.
[126] M. Maitland,et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] Natalie de Souza. Primer: induced pluripotency. , 2010, Nature methods.
[128] Stephan Beck,et al. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. , 2009, The international journal of biochemistry & cell biology.
[129] V. Ganapathy,et al. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. , 2009, The Biochemical journal.
[130] Sama F. Sleiman,et al. Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. , 2009, Expert opinion on investigational drugs.
[131] V. Ganapathy,et al. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.
[132] Lucia Altucci,et al. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. , 2009, The international journal of biochemistry & cell biology.
[133] Udayanath Aich,et al. Non-Natural Sugar Analogues: Chemical Probes for Metabolic Oligosaccharide Engineering , 2008 .
[134] B. Gajkowska,et al. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. , 2007, Advances in medical sciences.
[135] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[136] Peter A. Jones,et al. Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.
[137] S. Perrine. Fetal Globin Induction—Can It Cure β Thalassemia? , 2005 .
[138] Mark B. Jones,et al. Establishment of N‐Acetylmannosamine (ManNAc) Analogue‐Resistant Cell Lines as Improved Hosts for Sialic Acid Engineering Applications , 2004, Biotechnology progress.
[139] 寺尾 泰久. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells , 2002 .